Intellia Therapeutics (NASDAQ:NTLA) Hits New 52-Week Low - Here's Why

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $11.34 and last traded at $11.66, with a volume of 3223027 shares traded. The stock had previously closed at $11.41.

Analyst Ratings Changes

Several analysts recently weighed in on NTLA shares. William Blair reissued a "neutral" rating and set a $14.00 price target on shares of Intellia Therapeutics in a report on Monday, November 18th. Wedbush reaffirmed a "neutral" rating and set a $14.00 target price on shares of Intellia Therapeutics in a report on Monday, November 18th. Wells Fargo & Company lowered their price objective on Intellia Therapeutics from $80.00 to $70.00 and set an "overweight" rating on the stock in a research note on Monday, November 18th. Citigroup reduced their target price on Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating on the stock in a report on Friday, October 25th. Finally, The Goldman Sachs Group decreased their price target on Intellia Therapeutics from $31.00 to $20.00 and set a "neutral" rating on the stock in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $54.94.

Intellia Therapeutics Stock Up 2.2 %

The business has a 50-day moving average price of $14.23 and a two-hundred day moving average price of $19.58. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -2.14 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. During the same period in the previous year, the firm earned ($1.38) earnings per share. The company's revenue was down 24.1% on a year-over-year basis. On average, sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.

Institutional Trading of Intellia Therapeutics

Several institutional investors have recently made changes to their positions in NTLA. EverSource Wealth Advisors LLC lifted its holdings in Intellia Therapeutics by 763.5% during the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company's stock worth $39,000 after acquiring an additional 1,550 shares during the period. Eastern Bank purchased a new position in shares of Intellia Therapeutics in the 3rd quarter worth about $41,000. Values First Advisors Inc. bought a new stake in Intellia Therapeutics in the third quarter worth about $54,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Intellia Therapeutics by 27.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company's stock valued at $77,000 after purchasing an additional 794 shares during the period. Finally, KBC Group NV raised its stake in shares of Intellia Therapeutics by 37.3% in the third quarter. KBC Group NV now owns 3,753 shares of the company's stock valued at $77,000 after buying an additional 1,020 shares during the period. Institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.